ash highlights: glofitamab in dlbcl & pirtobrutinib and epcoritamab in richter's transformation
Published 1 year ago • 339 plays • Length 1:58Download video MP4
Download video MP3
Similar videos
-
4:31
updates in bispecifics for dlbcl from ash: glofitamab, odronextamab, epcoritamab & mosunetuzumab
-
1:38
phase ii study of epcoritamab in r/r lbcl
-
2:04
the starglo trial: glofitamab in combination with gemcitabine and oxaliplatin in r/r dlbcl
-
3:58
extended follow-up of glofitamab monotherapy in r/r lbcl: durability of cr and likelihood of crs
-
4:51
hot updates in r/r mcl at ash 2022: data on pirtobrutinib, glofitamab & zilovertamab
-
3:58
phase ib/iia study of azd4573 acalabrutinib in r/r dlbcl
-
0:41
ash 2021 highlights in cml
-
3:08
welcome to the video journal of hematology & hematological oncology 🎥🩸
-
6:59
will bispecific antibodies challenge car t-cell therapy in follicular lymphoma? - medpage today
-
29:38
dlbcl treatment approaches: what you need to know
-
2:31
a patient’s perspective on chronic myeloid leukemia (cml)
-
2:40
phase ii study of glofitamab in patients with r/r lbcl
-
2:43
insights into phase i/ii study assessing fixed-duration glofitamab treatment for r/r lbcl
-
3:08
aml highlights from ash 2017
-
1:21
hodgkin lymphoma highlights from ash 2023: nivo-avd versus bv-avd in patients with hl
-
5:30
glofitamab in r/r dlbcl: updated safety and efficacy data
-
1:14
highlights in quality management from ebmt
-
3:04
applying molecular understanding of dlbcl to management strategies
-
2:57
lymphoma highlights from ash 2021
-
2:18
update on phase i/ii study of glofitamab monotherapy in r/r mcl
-
1:14
ash 2014: managing diffuse large b-cell lymphoma